JP2025508944A5 - - Google Patents
Info
- Publication number
- JP2025508944A5 JP2025508944A5 JP2024551978A JP2024551978A JP2025508944A5 JP 2025508944 A5 JP2025508944 A5 JP 2025508944A5 JP 2024551978 A JP2024551978 A JP 2024551978A JP 2024551978 A JP2024551978 A JP 2024551978A JP 2025508944 A5 JP2025508944 A5 JP 2025508944A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- human subject
- cancer
- abiraterone
- decanoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315240P | 2022-03-01 | 2022-03-01 | |
| US63/315,240 | 2022-03-01 | ||
| US202263425839P | 2022-11-16 | 2022-11-16 | |
| US63/425,839 | 2022-11-16 | ||
| PCT/US2023/013116 WO2023167783A1 (en) | 2022-03-01 | 2023-02-15 | Abiraterone decanoate prodrugs and use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508944A JP2025508944A (ja) | 2025-04-10 |
| JP2025508944A5 true JP2025508944A5 (enExample) | 2026-02-25 |
Family
ID=85724851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551978A Pending JP2025508944A (ja) | 2022-03-01 | 2023-02-15 | アビラテロンプロドラッグ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250186463A1 (enExample) |
| EP (1) | EP4486353A1 (enExample) |
| JP (1) | JP2025508944A (enExample) |
| KR (1) | KR20240167653A (enExample) |
| CN (1) | CN119136813A (enExample) |
| AU (1) | AU2023229152A1 (enExample) |
| CA (1) | CA3243913A1 (enExample) |
| CL (1) | CL2024002613A1 (enExample) |
| CO (1) | CO2024013267A2 (enExample) |
| IL (1) | IL315174A (enExample) |
| MX (1) | MX2024010741A (enExample) |
| WO (1) | WO2023167783A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7850366B2 (ja) * | 2020-09-02 | 2026-04-23 | アステラス ユーエス エルエルシー | アビラテロンプロドラッグ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118684633A (zh) | 2018-10-18 | 2024-09-24 | 埃萨制药股份有限公司 | 雄激素受体调节剂及其使用方法 |
| JP7644713B2 (ja) * | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| CA3207282A1 (en) | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| CN118215466A (zh) * | 2021-09-08 | 2024-06-18 | 普洛佩拉治疗公司 | 口服阿比特龙制剂 |
-
2023
- 2023-02-15 KR KR1020247032828A patent/KR20240167653A/ko active Pending
- 2023-02-15 JP JP2024551978A patent/JP2025508944A/ja active Pending
- 2023-02-15 EP EP23712635.4A patent/EP4486353A1/en active Pending
- 2023-02-15 CN CN202380034399.2A patent/CN119136813A/zh active Pending
- 2023-02-15 IL IL315174A patent/IL315174A/en unknown
- 2023-02-15 WO PCT/US2023/013116 patent/WO2023167783A1/en not_active Ceased
- 2023-02-15 AU AU2023229152A patent/AU2023229152A1/en active Pending
- 2023-02-15 US US18/842,725 patent/US20250186463A1/en active Pending
- 2023-02-15 MX MX2024010741A patent/MX2024010741A/es unknown
- 2023-02-15 CA CA3243913A patent/CA3243913A1/en active Pending
-
2024
- 2024-08-30 CL CL2024002613A patent/CL2024002613A1/es unknown
- 2024-09-30 CO CONC2024/0013267A patent/CO2024013267A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study | |
| CN103476407A (zh) | 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症 | |
| JP7667132B2 (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| Kendra et al. | A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors | |
| US20200281923A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| De Maeseneer et al. | Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations | |
| CN110753545A (zh) | 用于前列腺癌的联合疗法 | |
| JP2023539371A5 (enExample) | ||
| JP2023542608A5 (enExample) | ||
| Goldman et al. | Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies | |
| JP2024533332A5 (enExample) | ||
| JP2026016396A (ja) | 乳がんの治療のための併用療法 | |
| Spies et al. | Prednisone chronotherapy | |
| Cathomas et al. | Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First‐Line Docetaxel: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (SAKK 08/11) | |
| Gong et al. | Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma | |
| TW202203913A (zh) | 使用包含ｇｄｃ—９４４５及ｃｄｋ４／６抑制劑之組合療法治療乳癌 | |
| US12350276B2 (en) | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| Anthony et al. | Diarrhea, constipation, and obstruction in cancer management | |
| Pyrgidis et al. | Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer | |
| Hadzi-Djokic | Hormone therapy for advanced prostate cancer | |
| WO2016172517A1 (en) | Methods of treating prostate cancer | |
| Yao et al. | Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study | |
| WO2023131894A1 (en) | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof | |
| KR20230165795A (ko) | 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법 | |
| RU2024129008A (ru) | Пролекарства абиратерона деканоата и их применение в терапии |